FOX Business’s Edward Lawrence reports on the Trump administration’s agreement with companies like Fujifilm to develop a coronavirus vaccine. Then, The Wall Street Journal editorial page deputy editor Dan Henninger looks at investing in biotech companies and the upcoming presidential election.
Johnson & Johnson announced Thursday that the first human clinical trials of its coronavirus vaccine candidate have begun in the United States and Belgium.
MODERNA LAUNCHES PHASE 3 VACCINE TRIAL
“We are excited to see these preclinical data because they show that our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” said Dr. Paul Stoffels, chief scientific officer of the company. . statement. “The findings give us confidence as we move forward with the development of our vaccine and luxury manufacturing in parallel, having started a Phase 1 / 2a trial in July with the intention of moving to a Phase 3 trial in September. “
| Heart | Security | Latest | Change | Change% |
|---|---|---|---|---|
| JNJ | JOHNSON AND JOHNSON | 146.49 | -0.05 | -0.03% |
Johnson & Johnson’s trials will include a “significant representation” of communities of color and the elderly, which have been disproportionately impacted by the virus, the company said.
A laboratory technician works during the coronavirus investigation at the Johnson & Johnson Janssen Pharmaceutical subsidiary in Beerse, Belgium, on Wednesday, June 17, 2020. (AP Photo / Virginia Mayo)
The pharmaceutical giant now has good news after a fall in earnings in the second quarter. The company saw a slowdown in demand for beauty products and medical devices, which affected its results.
CLICK HERE TO READ MORE ABOUT FOX BUSINESS
Twenty coronavirus vaccines are now in clinical trials, according to monitoring by the Milken Institute. Modern, based in the US, is one of the most advanced companies in vaccine development.
GET FOX BUSINESS ON THE MOVE BY CLICKING HERE
